News Item

  • Article
  • August 30, 2021

Author: Bret Stetka, MD Results from a new study suggest that a simple blood test can identify patients who are...

News Item

  • Article
  • August 19, 2021

Specialty drug spending contributes the largest share to rising healthcare costs. To make matters worse, in the case of rheumatoid...

News Item

  • Article
  • August 17, 2021

Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to...

News Item

  • Article
  • August 16, 2021

Q&A with Erin Connolly-Strong PhD, Head Medical Affairs Scipher Medicine via BiopharmaDive Multiple classes of drugs exist for treating rheumatoid...

News Item

  • Press Release
  • July 29, 2021

Expanded intended use for the blood test validated in Network-004 study. Now, most rheumatoid arthritis patients can be tested at...

News Item

  • Press Release
  • June 24, 2021

Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with Therapy Providers Can Access Patient-Specific Data for...

News Item

  • Press Release
  • June 15, 2021

• Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in...

News Item

  • Press Release
  • March 24, 2021

-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization...

News Item

  • Press Release
  • February 11, 2021

New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA...

News Item

  • Press Release
  • February 3, 2021

First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021 – WALTHAM, MA – Scipher Medicine, a...